BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …

Chronic anemia of cancer can be corrected in approximately 50% of the cases by treatment
with recombinant human erythropoietin (rHuEPO). Early prediction of responsiveness would …

Anaemia is frequently diagnosed in patients with cancer, and may have a detrimental effect
on quality of life (QoL). We previously conducted a systematic literature review (1996–2003) …

Recombinant human erythropoietin (EPO; epoetin) has been shown to be effective in
improving anemia in a proportion of cancer patients. The response rate is approximately …

Patients with cancer frequently develop anaemia, due either to the malignant disease itself
or to its treatment. Various factors, including the type of malignancy and the type and …

Approximately 50% of cancer patients develop anemia. In the past, the only available
treatment option for these patients was transfusion. Since the late 1980s, recombinant …

Background. Chronic anemia is a common complication in patients with cancer, especially
in those with advanced disease or who are under intensive chemotherapy. Because …

To test this possibility, we conducted a series of double-blind, placebo-controlled trials using
r-HuEPO in anaemic cancer patients in three different patient populations to examine the …

BACKGROUND: Since only a portion of anemic patients outside the uremia setting benefit
from erythropoietin treatment, a reliable means of predicting potential responders and …

Anaemia is frequently diagnosed in patients with cancer, yet it is difficult to identify a single
cause due to its multifactorial aetiology. We conducted a systematic literature review (1996 …